Startup IgGenix Inc. emerged from stealth mode with $10 million in Series A financing and a goal to advance the company’s novel antibody therapeutics platform for the treatment of food and non-food allergies, as well as other severe allergic conditions.
Locanabio combines gene therapy with RNA modification for a novel, highly flexible platform that can modify, replace or eliminate dysfunctional RNA.
Ohio-based startup Forge Biologics closed a $40 million Series A financing round that will be used to expand manufacturing capabilities and support the clinical development of a gene therapy program for rare diseases, including the typically fatal Krabbe disease.
With $30 million in Series A funding, Tranquis Therapeutics launches with a mission of revolutionizing the management of neurodegenerative and aging-related diseases through the advancement of a novel immuno-neurology treatment approach.
Baltimore-based AsclepiX Therapeutics closed a $35 million Series A financing.
San Diego-based Engrail Therapeutics launched with $32 million in a Series A financing round that was solely funded by Nan Fung Life Sciences (NFLS).
Lassen Therapeutics, based in San Diego, came out of stealth mode with a $31 million Series A financing round.
U.K.-based Bit Bio, a spinout of Cambridge University and previously known as Elpis Biotechnology, secured $41.5 million in a Series A funding round that will be used to support the company’s goal to transition biology into engineering.
Cambridge, Mass.-based QurAlis Corporation increased the company’s financial footing following a $42 million Series A financing round that will be used to support the continued development of therapeutic drugs for ALS and genetically related frontotemporal dementia (FTD).
Nearly two months after inking a licensing deal worth up to $1.5 billion with Swiss pharma giant Roche, Amunix Pharmaceuticals secured $73 million in an oversubscribed Series A financing round that will support the development of the company’s pipeline of novel T cell engagers (XPATs) and cytokines (XPACs).
